Schizophrenia Research
Volume 73, Issue 2 , Pages 139-145 , 1 March 2005

Suicidal risk during treatment with clozapine: a meta-analysis

  • John Hennen
    • ,
  • Ross J. Baldessarini

      Affiliations

    • Corresponding Author InformationCorresponding author. Mailman Research Center 306, McLean Hospital, 115 Mill Street, Belmont, MA 02478-9106, USA. Tel.: +1 617 855 3203; fax: +1 617 855 3479.

Received 12 September 2003 ,Revised 25 May 2004 ,Accepted 27 May 2004.

References 

  1. Allebeck P. Schizophrenia, a life-shortening disease. Schizophrenia Bull. 1989;15:81–89
  2. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E. Clinical variables related to suicide attempts in schizophrenic patients: retrospective study. Schizophrenia Res. 2003;60:47–55
  3. Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs. untreated bipolar and depressed patients: a preliminary report. Int. J. Psychiatr. Clin. Pract. 1998;2:115–119
  4. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J. Affect. Disord. 2002;68:167–181
  5. Baldessarini RJ, Frankenburg FR. Clozapine—a novel antipsychotic agent. N. Engl. J. Med. 1991;324:746–754
  6. In:  Baldessarini RJ,  Jamison KR editor. Effects of Medical Interventions on Suicidal Behavior. J. Clin. Psychiatry. vol. 60 (2 Suppl.):1999;p. 1–122
  7. Baldessarini RJ, Tondo L, Hennen J. Reduced suicide risk during long-term treatment with lithium. Ann. N.Y. Acad. Sci. 2001;932:24–43
  8. Baldessarini RJ, Hennen J, Kwok KW, Ioanitescu D, Ragade J, Tondo L, et al. Suicide risk and antidepressant treatment: A meta-analysis. 2004;(submitted for publication)
  9. Black DW, Fisher R. Mortality in DSM-III schizophrenia. Schizophrenia Res. 1992;7:109–116
  10. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bull. 1990;16:571–589
  11. Drake RE, Gates C, Whitaker A, Cotton PG. Suicide among schizophrenics: a review. Compr. Psychiatry. 1985;26:90–100
  12. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophrenia Res. 2001;47:127–134
  13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin. Trials. 1986;7:177–188
  14. Duggan A, Warner J, Knapp M, Kerwin R. Modeling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br. J. Psychiatry. 2003;182:505–508
  15. Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am. J. Psychiatry. 1997;154:199–204
  16. Food and Drug Administration of the United States (FDA) . Clozaril approved for reducing risk of suicide. FDA Consumer. 2003;37:5–6
  17. Glazer WM. Formulary decisions and health economics. J. Clin. Psychiatry. 1998;59(Suppl. 19):23–29
  18. In:  Goldsmith SK,  Pellmar TC,  Kleinman AM,  Bunney WE editor. Reducing Suicide. Washington, DC: Institute of Medicine of the US National Academy of Sciences; 2002;p. 33–68
  19. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467–1473
  20. Harkavy-Friedman JM, Nelson E. Management of suicidal patients with schizophrenia. Psychiatr. Clin. No. Am. 1997;20:625–640
  21. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br. J. Psychiatry. 1997;170:205–208
  22. Inskip HM, Harris EC, Barraclough B. Lifetime risk for suicide for affective disorders, alcoholism and schizophrenia. Br. J. Psychiatry. 1998;172:35–37
  23. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch. Gen. Psychiatry. 2000;57:311–317
  24. Kreyenbuhl JA, Kelly DL, Conley RR. Circumstances of suicide among individuals with schizophrenia. Schizophrenia Res. 2002;58:253–261
  25. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry. 1995;152:183–190
  26. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia. Arch. Gen. Psychiatry. 2003;60:82–91
  27. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Herwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Br. J. Psychiatry. 1999;175:576–580
  28. Pinikahana J, Happell B, Keks NA. Suicide and schizophrenia: review of literature for the decade 1990–1999: implications for mental health nursing. Issues Ment. Health Nurs. 2003;24:27–43
  29. Potkin SG, Alphs L, Hsu C, Krishnan KR, Anand R, Young FK, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective, two-year trial. Biol. Psychiatry. 2003;54:444–452
  30. Radomsky ED, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiatry. 1999;156:1590–1595
  31. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorders. Psychiatr. Serv. 1998;49:1029–1033
  32. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am. J. Psychiatry. 2001;158:931–937
  33. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophrenia Bull. 1996;22:485–499
  34. Siris S. Suicide and schizophrenia. J. Psychopharmacol. 2001;15:127–135
  35. Spivak B, Shabash E, Sheitman B, Weizman Q, Mester R. The effects of clozapine vs. haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, non-randomized, six-month study. J. Clin. Psychiatry. 2003;64:755–760
  36. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry. 1996;29:103–107
  37. Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. 2001;104:163–172
  38. Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491–511
  39. In:  Tsuang MT,  Tohen M editor. Textbook in Psychiatric Epidemiology. second edition. New York: Wiley; 2002;
  40. Wagstaff A, Perry C. Clozapine in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs. 2003;17:173–280
  41. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review ands meta-analysis of randomized trials. Am. J. Psychiatry. 1999;156:99–999
  42. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671–677

PII: S0920-9964(04)00182-3

doi: 10.1016/j.schres.2004.05.015

Schizophrenia Research
Volume 73, Issue 2 , Pages 139-145 , 1 March 2005

Article Tools

* Image Usage & Resolution